Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

RYTM Healthcare Biotechnology

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue: +79.6%
EPS: +26.9%
Free cash flow: +95.4%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

112.38 7.36 +7.01%

Follow RYTM

Alert me

Market cap: $7.3B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 6/9
Altman Z: 15.89
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. 10-K filed Feb 28, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 28, 2025 · accepted 8:19 AM ET · Document on sec.gov · Filing index

Red flags

Material weakness Feb 28, 2025
Rhythm Pharmaceuticals, Inc.’s 10-K reports a material weakness in internal control over financial reporting

In response to the identified material weakness above, we implemented measures designed to improve internal control over financial reporting to remediate the control deficiencies that led to our material weakness.

10-K filed Feb 28, 2025 · The filing · sec.gov